Clinical Trial Update: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL [Phase 2]

View source ↗

Summary

An ongoing Phase 2 study of PTX 100 in relapsed/refractory cutaneous T-cell lymphoma (CTCL) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• PTX-100 (PTX-100)

Snippet

Sponsor: Prescient Therapeutics, Ltd. | Conditions: CTCL | Phase 2 | Status: RECRUITING